Press releases
16 / 10 / 2017
19 / 09 / 2017
Twitter 
- @IpsenGroup I. Bocher-Pianka Chief Patient Affairs Officer @eyeforpharma Patient centricity our Modus Operandi https://t.co/yXcfNNdkeI
- @IpsenGroup RT @G5Sante: @garidel_de : "Très bonne chose que nouvelle Ministre de la santé @agnesbuzyn connaisse parfaitement monde santé & recherche"…
- @IpsenGroup RT @G5Sante: T.Eckenschwiller (Ipsen Italie) : L'Italie a pour ambition de devenir 1er pays UE pour la production #pharma en Europe, devant…
- @IpsenGroup #phase3 CELESTIAL trial of cabozantinib meets primary endpoint of overall survival in patients with advanced #HCC https://t.co/TcR1dTI3It
Executive Leadership Team
The Executive Leadership Team leads the Group business, in the areas of scientific, legal, financial, commercial and strategic matters.
RESEARCH & DEVELOPMENT
Ipsen’s commitment in research & development is our bold promise to patients, to launch at least one new drug or meaningful new indication every year.
Find a clinical trial >
